中国地区非铋联合四联疗法根除幽门螺杆菌:随机对照试验的荟萃分析。

PubMed ID
发表日期 2016年Jun月

原始出处 世界胃肠病学杂志
World journal of gastroenterology
作者 Lin  Lien-Chieh  Hsu  Tzu-Herng  Huang  Kuang-Wei  Tam  Ka-Wai 

文献标题 中国地区非铋联合四联疗法根除幽门螺杆菌:随机对照试验的荟萃分析。
Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials.

文献摘要 AIM

目的探讨非铋联合四联疗法根除幽门螺杆菌(H.pylori)在中国地区的适用性。

METHODS

采用系统回顾和荟萃分析方法,对中国地区非铋联合序贯疗法和三联疗法根除幽门螺杆菌的疗效进行了评价。中国定义的地区包括中国、香港、台湾和新加坡。主要结果是幽门螺杆菌根除率;次要结果是治疗依从性。在PubMed、Embase、Scopus和Cochrane数据库中搜索到截至2016年3月的研究,没有语言限制。

RESULTS

我们回顾了6个随机对照试验和1616例患者。在3个对比联合四联疗法和三联疗法的试验中,7-d非铋联合四联疗法的幽门螺杆菌根除率显著高于7-d三联疗法(91.2%vs 77.9%,风险比=1.17,95%CI:1.09-1.25)。在3个比较四联疗法和序贯疗法的试验中,两组的根除率(86.9%对86.0%)没有显著性差异。然而,与序贯疗法相比,联合疗法获得了更高的依从性。

CONCLUSION

非铋联合四联疗法的幽门螺杆菌根除率高于三联疗法。此外,与序贯疗法相比,非铋联合四联疗法获得了更高的依从性。因此,非铋联合四联疗法应成为中国地区的一线治疗方法。


AIM

To evaluate the applicability of nonbismuth concomitant quadruple therapy for Helicobacter pylori (H. pylori) eradication in Chinese regions.

METHODS

A systematic review and meta-analysis of randomized controlled trials was performed to evaluate the efficacy of nonbismuth concomitant quadruple therapy between sequential therapy or triple therapy for H. pylori eradication in Chinese regions. The defined Chinese regions include China, Hong Kong, Taiwan, and Singapore. The primary outcome was the H. pylori eradication rate; the secondary outcome was the compliance with therapy. The PubMed, Embase, Scopus, and Cochrane databases were searched for studies published in the period up to March 2016 with no language restriction.

RESULTS

We reviewed six randomized controlled trials and 1616 patients. In 3 trials comparing concomitant quadruple therapy with triple therapy, the H. pylori eradication rate was significantly higher for 7-d nonbismuth concomitant quadruple therapy than for 7-d triple therapy (91.2% vs 77.9%, risk ratio = 1.17, 95%CI: 1.09-1.25). In 3 trials comparing quadruple therapy with sequential therapy, the eradication rate was not significant between groups (86.9% vs 86.0%). However, higher compliance was achieved with concomitant therapy than with sequential therapy.

CONCLUSION

The H. pylori eradication rate was higher for nonbismuth concomitant quadruple therapy than for triple therapy. Moreover, higher compliance was achieved with nonbismuth concomitant quadruple therapy than with sequential therapy. Thus, nonbismuth concomitant quadruple therapy should be the first-line treatment in Chinese regions.


获取全文 10.3748/wjg.v22.i23.5445